Our Research Publications
Updated November 2023
Pagination
- Previous page
- Page 8
- Next page
Title Sort descending | Authors | Year | Journal | Link to Article | Intended Audience | Purpose |
---|---|---|---|---|---|---|
CD44 Antibody Inhibition of Macrophage Phagocytosis Targets Fc? Receptor– and Complement Receptor 3–Dependent Mechanisms | Amash A, Wang L, Wang Y, Bhakta V, Fairn GD, Hou M, Peng J, Sheffield WP, Lazarus AH | 2016 | J Immunol | View CD44 Antibody Inhibition of Macrophage Phagocytosis Targets Fc? Receptor– and Complement Receptor 3–Dependent Mechanisms | Researchers | Basic research |
CD44 antibody-mediated amelioration of murine immune thrombocytopenia (ITP): mouse background determines the effect of FcgammaRIIb genetic disruption | Crow AR, Amash A, Lazarus AH | 2014 | Transfusion | View CD44 antibody-mediated amelioration of murine immune thrombocytopenia (ITP): mouse background determines the effect of FcgammaRIIb genetic disruption | Researchers | Basic research |
CD8(+) T cells induce platelet clearance in the liver via platelet desialylation in immune thrombocytopenia | Qiu J, Liu X, Li X, Zhang X, Han P, Zhou H, Shao L, Hou Y, Min Y, Kong Z, Wang Y, Wei Y, Liu X, Ni H, Peng J, Hou M | 2016 | Sci Rep | View CD8(+) T cells induce platelet clearance in the liver via platelet desialylation in immune thrombocytopenia | Researchers | Basic research |
CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia | Ma L, Simpson E, Li J, Xuan M, Xu M, Baker L, Shi Y, Yougbaré I, Wang X, Zhu G, Chen P, Prudhomme GJ, Lazarus AH, Freedman J, Ni H | 2015 | Blood | View CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia | Researchers | Basic research |
Cell-based therapy using umbilical cord blood for novel indications in regenerative therapy and immune modulation: an updated systematic scoping review of the literature | Rizk M, Aziz J, Shorr R, Allan DS | 2017 | Biol Blood Marrow Transplant | View Cell-based therapy using umbilical cord blood for novel indications in regenerative therapy and immune modulation: an updated systematic scoping review of the literature | Researchers | Clinical research |
Cell-matrix interactions of Factor IX (FIX)-engineered human mesenchymal stromal cells encapsulated in RGD-alginate vs. Fibrinogen-alginate microcapsules | Sayyar B, Dodd M, Marquez-Curtis L, Janowska-Wieczorek A, Hortelano G | 2014 | Artif Cells Nanomed Biotechnol | View Cell-matrix interactions of Factor IX (FIX)-engineered human mesenchymal stromal cells encapsulated in RGD-alginate vs. Fibrinogen-alginate microcapsules | Researchers | Basic research |
Cellular immune dysfunction in immune thrombocytopenia (ITP) | McKenzie CGJ, Guo L, Freedman J, Semple JW | 2013 | Br J Haematol | View Cellular immune dysfunction in immune thrombocytopenia (ITP) | Researchers | Basic research |
Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin-induced thrombocytopenia | Nazy I, Clare R, Staibano P, Warkentin TE, Larché M, Moore JC, Smith JW, Whitlock RP, Kelton JG, Arnold DM | 2018 | J Thromb Haemost | View Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin-induced thrombocytopenia | Researchers | Clinical research |
Centre d’innovation Rapport d’étape annuel 2019-2020 | Levy I, Pambrun C | 2020 | Blood.ca website | Other | Other | |
Centre for Innovation Annual Progress Report 2019-2020 | Levy I, Pambrun C | 2020 | Blood.ca website | Other | Other | |
Cerebral venous sinus thrombosis associated with spontaneous heparin-induced thrombocytopenia syndrome after total knee arthroplasty | Hwang SR, Wang Y, Weil EL, Padmanabhan A, Warkentin TE, Pruthi RK | 2020 | Platelets | View Cerebral venous sinus thrombosis associated with spontaneous heparin-induced thrombocytopenia syndrome after total knee arthroplasty | Health care providers | Clinical research |
Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company | Hay CRM, Shima M, Makris M, Jiménez-Yuste V, Oldenburg J, Fischer K, Iorio A, Skinner MW, Santagostino E, von Mackensen S, Kessler CM | 2020 | Haemophilia | View Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company | Researchers | Clinical research |
Challenges in Detecting Clinically Relevant Heparin-Induced Thrombocytopenia Antibodies | Warkentin TE | 2020 | Hämostaseologie | View Challenges in Detecting Clinically Relevant Heparin-Induced Thrombocytopenia Antibodies | Health care providers | Clinical research |
Challenges in the management of the blood supply | Williamson LM, Devine DV | 2013 | Lancet | View Challenges in the management of the blood supply | Blood operators | Other |
Challenging the 30-min rule for thawed plasma | Ramirez-Arcos S, Howell A, Bearne J, Bhakta V, Bower L, Cardigan R, Girard M, Kou Y, McDonald C, Nolin M-È, Sawicka D, Sheffield W | 2021 | Vox Sang | View Challenging the 30-min rule for thawed plasma | Researchers | Benchmarking and standard setting |
Changes in blood center red blood cell distributions in the era of patient blood management: the trends for collection (TFC) study | Yazer MH, Jackson B, Beckman N, Chesneau S, Bowler P, Delaney M, Devine D, Field S, Germain M, Murphy MF, Sayers M, Shaz B, Shinar E, Takanashi M, Vassallo R, Wickenden C, Yahalom V, Land K, on behalf of the BEST Collaborative | 2016 | Transfusion | View Changes in blood center red blood cell distributions in the era of patient blood management: the trends for collection (TFC) study | Blood operators | New or improved product or process |
Changes in coagulation factor activity and content of di(2-ethylhexyl)phthalate in frozen plasma units during refrigerated storage for up to five days after thawing | Sheffield WP, Bhakta V, Mastronardi C, Ramirez-Arcos S, Howe D, Jenkins C | 2012 | Transfusion | View Changes in coagulation factor activity and content of di(2-ethylhexyl)phthalate in frozen plasma units during refrigerated storage for up to five days after thawing | Health care providers | New or improved product or process |
Changes in minimum hemoglobin and interdonation interval: impact on donor hemoglobin and donation frequency | Goldman M, Yi Q-L, Steed T, O'Brien SF | 2019 | Transfusion | View Changes in minimum hemoglobin and interdonation interval: impact on donor hemoglobin and donation frequency | Researchers | New or improved product or process |
Changes in plasma unit distributions to hospitals over a 10-year period | Seheult JN, Shaz B, Bravo M, Croxon H, Devine D, Doncaster C, Field S, Flanagan P, Germain M, Gregoire Y, Kamel H, Karafin M, Kelting N, Lewis M, O'Brien C, Murphy MF, Rossmann S, Sayers M, Shinar E, Takanashi M, Titlestad K, Yazer MH | 2018 | Transfusion | View Changes in plasma unit distributions to hospitals over a 10-year period | Blood operators | Clinical research |
Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era | Reedman CN, Drews SJ, Yi Q-L, Pambrun C, O’Brien SF | 2022 | Microbiol Spectr | View Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era | Researchers | Clinical research |
Changing the 30-min Rule in Canada: The Effect of Room Temperature on Bacterial Growth in Red Blood Cells | Ramirez-Arcos S, Kou Y, Ducas É, Thibault L | 2016 | Transfus Med Hemother | View Changing the 30-min Rule in Canada: The Effect of Room Temperature on Bacterial Growth in Red Blood Cells | Blood operators | Benchmarking and standard setting |
Changing the deferral for men who have sex with men - an improved model to estimate HIV residual risk | Davison KL, Gregoire Y, Germain M, Custer B, O'Brien SF, Steele WR, Pillonel J, Seed CR | 2019 | Vox Sang | View Changing the deferral for men who have sex with men - an improved model to estimate HIV residual risk | Blood operators | New or improved product or process |
Changing trends in blood transfusion: an analysis of 244,013 hospitalizations | Shehata N, Forster A, Lawrence N, Rothwell DM, Fergusson D, Tinmouth A, Wilson K | 2014 | Transfusion | View Changing trends in blood transfusion: an analysis of 244,013 hospitalizations | Health care providers | Clinical research |
Chapitre 10. Les réactions transfusionnelles | Laureano M, Khandelwal A, Yan M | 2022 | Guide de la pratique transfusionnelle | View Chapitre 10. Les réactions transfusionnelles | Health care providers | Benchmarking and standard setting |
Chapitre 14. Aphérèse thérapeutique | Oliver M, Patriquin C | 2023 | Guide de la pratique transfusionnelle | View Chapitre 14. Aphérèse thérapeutique | Health care providers | Benchmarking and standard setting |
Chapitre 15: Composants sanguins négatifs pour les anti-CMV, irradiés et lavéss | Prokopchuk-Gauk O, Solh Z | 2021 | Guide de la pratique transfusionnelle | View Chapitre 15: Composants sanguins négatifs pour les anti-CMV, irradiés et lavéss | Health care providers | Benchmarking and standard setting |
Chapitre 19. Plaquettes à teneur réduite en agents pathogènes | Blais-Normandin I, Tordon B, Anani W, Ning S | 2022 | Guide de la pratique transfusionnelle | View Chapitre 19. Plaquettes à teneur réduite en agents pathogènes | Health care providers | Benchmarking and standard setting |
Chapitre 2: Les composants sanguins | Gupta A, Bigham M | 2021 | Guide de la pratique transfusionnelle | View Chapitre 2: Les composants sanguins | Health care providers | Benchmarking and standard setting |
Chapitre 5. Concentrés pour les troubles de l’hémostase et l’angiœdème héréditaire | Poon MC, Goodyear D, Rydz N, Lee A | 2022 | Guide de la pratique transfusionnelle | View Chapitre 5. Concentrés pour les troubles de l’hémostase et l’angiœdème héréditaire | Health care providers | Benchmarking and standard setting |
Chapitre 6: Sélection des donneurs, dépistage des maladies transmissibles et réduction des agents pathogènes | Drews S, Khandelwal A, Goldman M, Devine D | 2021 | Guide de la pratique transfusionnelle | View Chapitre 6: Sélection des donneurs, dépistage des maladies transmissibles et réduction des agents pathogènes | Health care providers | Benchmarking and standard setting |
Chapter 10. Transfusion reactions | Laureano M, Khandelwal A, Yan M | 2022 | Clinical Guide to Transfusion | View Chapter 10. Transfusion reactions | Health care providers | Benchmarking and standard setting |
Chapter 11: Massive hemorrhage and emergency transfusion | Trudeau J, Dawe P, Shih A | 2021 | Clinical Guide to Transfusion | View Chapter 11: Massive hemorrhage and emergency transfusion | Health care providers | Benchmarking and standard setting |
Chapter 14. Therapeutic apheresis | Oliver M, Patriquin C | 2023 | Clinical Guide to Transfusion | View Chapter 14. Therapeutic apheresis | Health care providers | Benchmarking and standard setting |
Chapter 16: Preoperative autologous donation | Foster T, Yan M | 2021 | Clinical Guide to Transfusion | View Chapter 16: Preoperative autologous donation | Health care providers | Benchmarking and standard setting |
Chapter 17. Hemostatic disorders and hereditary angioedema | Poon MC, Goodyear D, Rydz N, Lee A | 2022 | Clinical Guide to Transfusion | View Chapter 17. Hemostatic disorders and hereditary angioedema | Health care providers | Benchmarking and standard setting |
Chapter 17. Troubles de l’hémostase et angiœdème héréditaire | Poon MC, Goodyear D, Rydz N, Lee A | 2022 | Guide de la pratique transfusionnelle | View Chapter 17. Troubles de l’hémostase et angiœdème héréditaire | Health care providers | Benchmarking and standard setting |
Chapter 19. Pathogen-reduced platelets | Blais-Normandin I, Tordon B, Anani W, Ning S | 2022 | Clinical Guide to Transfusion | View Chapter 19. Pathogen-reduced platelets | Health care providers | Benchmarking and standard setting |
Chapter 2. Blood components | Gupta A, Bigham M | 2023 | Clinical Guide to Transfusion | View Chapter 2. Blood components | Health care providers | Benchmarking and standard setting |
Chapter 2: Blood components | Gupta A, Bigham M | 2021 | Clinical Guide to Transfusion | View Chapter 2: Blood components | Health care providers | Benchmarking and standard setting |
Chapter 33: Synthesis of N-(4-Methoxybenzyl)-2-(α-d-glucopyranosyl) acetamide | Roy R, Vidal S, Briard JG, Shiao TC, Ben RN | 2015 | Carbohydrate Chemistry: Proven Synthetic Methods, Volume 3 | View Chapter 33: Synthesis of N-(4-Methoxybenzyl)-2-(α-d-glucopyranosyl) acetamide | Researchers | Basic research |
Chapter 4: Clinical transfusion procedures | Clarke G, Al-Riyami AZ, Roxby D | 2021 | Educational Modules on Clinical Use of Blood | View Chapter 4: Clinical transfusion procedures | Health care providers | Benchmarking and standard setting |
Chapter 5 - Platelet microRNAs | Provost P | 2013 | Platelets (Third Edition) | View Chapter 5 - Platelet microRNAs | Researchers | Other |
Chapter 5. Concentrates for hemostatic disorders and hereditary angioedema | Poon MC, Goodyear D, Rydz N, Lee A | 2022 | Clinical Guide to Transfusion | View Chapter 5. Concentrates for hemostatic disorders and hereditary angioedema | Health care providers | Benchmarking and standard setting |
Chapter 6: Donor selection, donor testing and pathogen reduction | Drews S, Khandelwal A, Goldman M, Devine D | 2021 | Clinical Guide to Transfusion | View Chapter 6: Donor selection, donor testing and pathogen reduction | Health care providers | Benchmarking and standard setting |
Chaptire 16: Don autologue préopératoire | Foster T, Yan M | 2021 | Guide de la pratique transfusionnelle | View Chaptire 16: Don autologue préopératoire | Health care providers | Benchmarking and standard setting |
Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects | Huynh A, Arnold DM, Smith JW, Moore JC, Zhang A, Chagla Z, Harvey BJ, Stacey HD, Ang JC, Clare R, Ivetic N, Chetty VT, Bowdish DME, Miller MS, Kelton JG, Nazy I | 2021 | Viruses | View Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects | Researchers | Clinical research |
Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S | Huynh A, Arnold DM, Michael JV, Clare R, Smith JW, Daka M, Ianosi-Irimie M, McKenzie SE, Kelton JG, Nazy I | 2023 | Blood Adv | View Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S | Researchers | Clinical research |
Characterization of a long-acting recombinant human serum albumin-atrial natriuretic factor (ANF) expressed in Pichia pastoris | de Bold MK, Sheffield WP, Martinuk A, Bhakta V, Eltringham-Smith L, de Bold AJ | 2012 | Regul Pept | View Characterization of a long-acting recombinant human serum albumin-atrial natriuretic factor (ANF) expressed in Pichia pastoris | Researchers | Basic research |
Characterization of CD41(+) cells in the lymph node | Dai L, Uehara M, Li X, LaBarre BA, Banouni N, Ichimura T, Lee-Sundlov MM, Kasinath V, Sullivan JA, Ni H, Barone F, Giannini S, Bahmani B, Sage PT, Patsopoulos NA, Tsokos GC, Bromberg JS, Hoffmeister K, Jiang L, Abdi R | 2022 | Front Immunol | View Characterization of CD41(+) cells in the lymph node | Researchers | Basic research |
Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia | Huynh A, Arnold DM, Kelton JG, Smith JW, Horsewood P, Clare R, Guarné A, Nazy I | 2018 | J Thromb Haemost | View Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia | Researchers | Basic research |